January 20, 2025 A class action claims Go & Grow and Pure Bliss Toddler Drinks by Similac faces are falsely advertised as healthy for children between 12 and 36 months.
September 17, 2024 Abbott Laboratories faces a class action over its alleged use of tracking tools on FreeStyle.Abbott.com that expose consumers’ private information.
September 6, 2024 A class action alleges the labels of Similac Go & Grow 360 Total Care toddler drinks display nutrient content claims that are prohibited by the FDA.
May 17, 2023 A class action alleges PediaSure Grow & Gain is falsely advertised given that no evidence exists to support the claim that it is “clinically proven” to help increase a child’s height.
September 14, 2022 Ovulation test makers faces a class action that alleges the companies have misleadingly advertised the accuracy of the products to capitalize on buyers’ “reproductive anxiety.”
July 7, 2022 A proposed class action claims that following the mixing instructions on containers of Similac Powder Formula will not yield as many bottles as advertised.
February 18, 2022 Abbott Laboratories faces a proposed class action in the wake of a voluntary recall of its Similac, Alimentum and EleCare powdered infant formulas.
November 22, 2021 A class action alleges certain label claims touting Similac Pro-Advance infant formula as able to confer benefits the same as or similar to those of breast milk are false and misleading.
December 2, 2020 A class action alleges Abbott Labs has misleadingly labeled its Similac Go & Grow toddler drink in a manner that's "confusingly similar" to its infant formula.
December 7, 2017 Purdue Pharma, L.P., and three others have been named as defendants in a proposed class action that claims they misrepresented the efficacy and risks of using opioids for long-term and chronic pain management.
November 16, 2017 Another proposed class action has been filed against various pharmaceutical companies and distributors, claiming the defendants’ deceptive marketing of opioid products has contributed to their widespread abuse.
November 16, 2017 A proposed class action has been filed against a group of pharmaceutical companies and distributors over claims that they deceptively marketed and sold opioids without fully disclosing their associated risks.
